Rutkove SB, Kapur K, Zaidman C, Wu JS, Pasternak A, Madabusi
L, Yim S, Pacheck A, Szelag H, Harrington T, Darras BT. Electrical impedance
myography for assessment of Duchenne muscular dystrophy. Ann Neurol. 2017
Jan 11. doi:10.1002/ana.24874. [Epub ahead of print]
Abstract
OBJECTIVE:
Sensitive, objective and easily applied methods for
evaluating disease progression and response to therapy are needed for clinical
trials in Duchenne muscular dystrophy (DMD). In this study, we evaluated
whether electrical impedance myography (EIM) could serve this purpose.
METHODS:
In this non-blinded study, 36 boys with DMD and 29
age-similar healthy boys underwent multifrequency EIM measurements for up to 2
years on 6 muscles unilaterally along with functional assessments. A linear
mixed-effects model with random intercept and slope terms was used for the
analysis of multifrequency EIM values and functional measures. Seven DMD boys
were initiated on corticosteroids; these data were analyzed using a piecewise
linear mixed-effects model.
RESULTS:
In boys >7.0 years, a significant difference in the slope
of EIM phase-ratio trajectories in the upper extremity was observed by 6 months
of -0.074/month, p=0.023, 95% confidence interval (CI)[-0.013,-0.14]); at two
years, this difference was -0.048/month, p<0.0001 95%CI[-0.028,-0.068]. In
boys ≤7.0 years, differences appeared at 6 months in gastrocnemius (EIM
phase-slope -0.83°/kHz-month, p=0.007 95%CI[-0.26,-1.40]). EIM outcomes showed
significant differences earlier than functional tests. Initiation of
corticosteroids significantly improved the slope of EIM phase-ratio
(0.057/month, p=0.00019 95%CI[0.028,0.086]) and EIM phase-slope
(0.14°/kHz-month, p=0.013 95%CI[0.028,0.25]), consistent with corticosteroids'
known clinical benefit.
INTERPRETATION:
EIM detects deterioration in muscles of both younger and
older boys by 6 months; it also identifies the therapeutic effect of
corticosteroid initiation. Since EIM is rapid to apply, painless, and requires
minimal operator training, the technique deserves to be further evaluated as a
biomarker in DMD clinical therapeutic trials.
No comments:
Post a Comment